PIRS
Price:
$17.04
Market Cap:
$22.50M
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; ...[Read more]
Industry
Biotechnology
IPO Date
2015-01-02
Stock Exchange
NASDAQ
Ticker
PIRS
According to Pieris Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.89. This represents a change of 1.99% compared to the average of -0.87 of the last 4 quarters.
The mean historical PE Ratio of Pieris Pharmaceuticals, Inc. over the last ten years is -6.31. The current -0.89 PE Ratio has changed 1.31% with respect to the historical average. Over the past ten years (40 quarters), PIRS's PE Ratio was at its highest in in the December 2017 quarter at 11.30. The PE Ratio was at its lowest in in the September 2014 quarter at -1887.66.
Average
-6.31
Median
-5.44
Minimum
-18.80
Maximum
-0.67
Discovering the peaks and valleys of Pieris Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 631.04%
Maximum Annual PE Ratio = -0.67
Minimum Annual Increase = -100.67%
Minimum Annual PE Ratio = -18.80
Year | PE Ratio | Change |
---|---|---|
2023 | -0.67 | -72.94% |
2022 | -2.47 | -56.13% |
2021 | -5.63 | 53.79% |
2020 | -3.66 | -52.58% |
2019 | -7.71 | 46.18% |
2018 | -5.28 | -71.92% |
2017 | -18.80 | 631.04% |
2016 | -2.57 | -54.11% |
2015 | -5.60 | -47.49% |
2014 | -10.67 | -100.67% |
The current PE Ratio of Pieris Pharmaceuticals, Inc. (PIRS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.92
5-year avg
-4.03
10-year avg
-6.31
Pieris Pharmaceuticals, Inc.’s PE Ratio is greater than Adaptimmune Therapeutics plc (-3.82), greater than Mereo BioPharma Group plc (-18.18), greater than PDS Biotechnology Corporation (-2.64), greater than Leap Therapeutics, Inc. (-1.83), less than X4 Pharmaceuticals, Inc. (7.41), greater than Corvus Pharmaceuticals, Inc. (-10.64), greater than Terns Pharmaceuticals, Inc. (-6.06), less than TCR2 Therapeutics Inc. (-0.44), less than Affimed N.V. (-0.66), greater than ADC Therapeutics SA (-1.20), less than Agenus Inc. (-0.47), greater than Inozyme Pharma, Inc. (-3.48), less than Achilles Therapeutics plc (-0.45), greater than Checkpoint Therapeutics, Inc. (-1.81), less than Cue Biopharma, Inc. (-0.63), greater than Medicenna Therapeutics Corp. (-1.05),
Company | PE Ratio | Market cap |
---|---|---|
-3.82 | $278.72M | |
-18.18 | $664.26M | |
-2.64 | $107.88M | |
-1.83 | $107.52M | |
7.41 | $109.78M | |
-10.64 | $252.08M | |
-6.06 | $549.60M | |
-0.44 | $58.11M | |
-0.66 | $57.26M | |
-1.20 | $260.95M | |
-0.47 | $106.78M | |
-3.48 | $312.42M | |
-0.45 | $29.58M | |
-1.81 | $93.07M | |
-0.63 | $28.70M | |
-1.05 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Pieris Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Pieris Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Pieris Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Pieris Pharmaceuticals, Inc. (PIRS)?
What is the highest PE Ratio for Pieris Pharmaceuticals, Inc. (PIRS)?
What is the 3-year average PE Ratio for Pieris Pharmaceuticals, Inc. (PIRS)?
What is the 5-year average PE Ratio for Pieris Pharmaceuticals, Inc. (PIRS)?
How does the current PE Ratio for Pieris Pharmaceuticals, Inc. (PIRS) compare to its historical average?